You are here: Industry Insights > Immuno-Oncology

News List

‘Hit-and-run’ gene therapy nanoparticles could enhance CAR-T treatments fiercebiotech
August 31, 2017
Fred Hutch scientists are using nanoparticles to improve engineered cells such as CAR-T cells.
Arcus adds WuXi Biologics-developed PD-1 drug under $816M deal fiercebiotech
August 21, 2017
In a potential $816 million deal, Arcus Biosciences gets exclusive rights to a PD-1 drug by Chinese firms WuXi Biologics and Gloria Pharmaceuticals.
Five Prime names ex-Genentech I-O specialist research SVP fiercebiotech
August 21, 2017
Bryan Irving replaces Luis Borges as SVP of research.
Cancer Genetics pays $12M for Australian CRO vivoPharm fiercebiotech
August 18, 2017
The deal sees CGI boost its immuno-oncology offerings.
Takeda Allies with Austin for 'double whammy' cancer immunotherapies fiercebiotech
August 14, 2017
The deal adds to a long list of alliances between Takeda and small biotechs.
Sutro, Celgene to Refocus 2014 Immuno-Oncology Collaboration americanpharmaceuticalreview
August 11, 2017
Sutro Biopharma announced it is refocusing its 2014 immuno-oncology collaboration with Celgene on four programs that are advancing through preclinical development, including an antibody drug conjugate (ADC) program targeting B-Cell maturation antigen (BCM
Is 2017 set to be the year we see a CAR-T therapy approved? Let’s find out from the leaders in the f fiercepharma
July 21, 2017
Using your body’s own cells, engineering them to target tumors and cure cancer sounds like something from a Sci-Fi movie but it’s not, it’s happening right now!
Merck Ventures creates new immuno-oncology company iOnctura cphi-online
June 23, 2017
iOnctura is set up to develop a pipeline of assets targeting immunosuppression in the tumour microenvironment.
Merck Ventures creates new immuno-oncology company iOnctura worldpharmanews
June 21, 2017
Merck, a leading science and technology company, today announced its corporate venture arm Merck Ventures created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Mer
Pierre Fabre Buys Igenica Immuno-oncology Assets contractpharma
May 26, 2017
Deal reinforces Pierre Fabre’s pipeline in oncology, its primary R&D focus area

Previous page 1 2 3 4 5 6 7 8 9 10 Next page